We characterize potential targetable AD-O51.4 resistance mechanisms and propose HDAC, dynamin and BCL2 inhibitors as pharmacological modulators with a potential to restore the sensitivity to TRAIL-induced apoptosis. The gene discussed is BCL2; the disease is Alzheimer disease.